Status:
COMPLETED
Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides
Lead Sponsor:
Pevion Biotech Ltd
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Pevion Biotech has designed a therapeutic vaccine to treat patients who suffer from chronic hepatitis C virus infection. The vaccine is based on a combination of the PeviPRO and PeviTER platforms usin...
Eligibility Criteria
Inclusion
- Healthy volunteers of both sexes
- Aged between 18 and 45 years
- Free of obvious health problems
- With a BMI between 18.5 and 29.9 are included if they give written informed consent
Exclusion
- Chronic or acute illness
- Immunosuppression
- HCV and/or HBV infection
- history of allergic disease
- Pre-existing immune response against peptide of the vaccines
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00445419
Start Date
December 1 2006
End Date
June 1 2008
Last Update
February 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vaccine and Immunotherapy Center, CHUV
Lausanne, Switzerland, 1011